Literature DB >> 26678189

Precision oncology: where next?

Martin Gore1, James Larkin2.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26678189     DOI: 10.1016/S1470-2045(15)00473-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.

Authors:  Alexandre Vivot; Isabelle Boutron; Geoffroy Béraud-Chaulet; Jean-David Zeitoun; Philippe Ravaud; Raphaël Porcher
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

2.  CARF enrichment promotes epithelial-mesenchymal transition via Wnt/β-catenin signaling: its clinical relevance and potential as a therapeutic target.

Authors:  Rajkumar S Kalra; Anupama Chaudhary; A-Rum Yoon; Priyanshu Bhargava; Amr Omar; Sukant Garg; Chae-Ok Yun; Sunil C Kaul; Renu Wadhwa
Journal:  Oncogenesis       Date:  2018-05-11       Impact factor: 7.485

3.  Sequential filtering for clinically relevant variants as a method for clinical interpretation of whole exome sequencing findings in glioma.

Authors:  Ege Ülgen; Özge Can; Kaya Bilguvar; Cemaliye Akyerli Boylu; Şirin Kılıçturgay Yüksel; Ayça Erşen Danyeli; O Uğur Sezerman; M Cengiz Yakıcıer; M Necmettin Pamir; Koray Özduman
Journal:  BMC Med Genomics       Date:  2021-02-23       Impact factor: 3.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.